Chemotherapy-Induced Peripheral Neuropathy Survey
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01016028|
Recruitment Status : Withdrawn (Study assessment tool development delayed.)
First Posted : November 18, 2009
Last Update Posted : May 3, 2016
|Condition or disease||Intervention/treatment|
|Breast Cancer Colorectal Cancer Myeloma Chemotherapy-induced Peripheral Neuropathy||Behavioral: Questionnaire Behavioral: Sensory Tests Behavioral: Interview|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||February 2013|
|Questionnaire + Sensory Tests + Interview||
3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
Other Name: Survey
Behavioral: Sensory Tests
Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
- Assessment of Patient's Symptoms (Questionnaire) [ Time Frame: Each patient administered questionnaire at single point in time. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01016028
|Principal Investigator:||Charles Cleeland, PHD,BA||UT MD Anderson Cancer Center|